Bright Minds Biosciences Inc. (NASDAQ:DRUG) Sees Large Growth in Short Interest
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Sees Large Growth in Short Interest
Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) was the recipient of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 758,600 shares, a growth of 58.5% from the October 15th total of 478,500 shares. Based on an average trading volume of 12,300,000 shares, the short-interest ratio is currently 0.1 days. Approximately 10.1% of the company's shares are sold short.
光明之心生物科学公司(纳斯达克：毒品获得评级)是空头股数在10月份实现显著增长的接受者。截至10月31日，空头股数共有75.86万股，比10月15日的47.85万股增长了58.5%。以12,300,000股的平均成交量计算，目前短息比为0.1天。该公司约10.1%的股票被卖空。
Bright Minds Biosciences Price Performance
Bright Minds生物科学的价格表现
NASDAQ DRUG traded up $0.07 during mid-day trading on Friday, reaching $1.12. 404,034 shares of the stock were exchanged, compared to its average volume of 1,332,820. Bright Minds Biosciences has a one year low of $0.75 and a one year high of $8.30. The stock has a 50 day simple moving average of $1.19 and a 200-day simple moving average of $1.13.
纳斯达克药品在周五午盘交易中上涨0.07美元，达到1.12美元。该股成交量为404,034股，而平均成交量为1,332,820股。Bright Minds Biosciences的一年低点为0.75美元，一年高位为8.30美元。该股的50日简单移动均线切入位在1.19美元，200日简单移动均线切入位在1.13美元。
Bright Minds Biosciences (NASDAQ:DRUG – Get Rating) last announced its earnings results on Friday, August 12th. The company reported ($0.17) earnings per share for the quarter.
光明心灵生物科学(纳斯达克：药物获得评级)最近一次公布财报是在8月12日(星期五)。该公司公布了本季度每股收益(0.17美元)。
Hedge Funds Weigh In On Bright Minds Biosciences
对冲基金对Bright Minds生物科学的看法
About Bright Minds Biosciences
关于Bright Minds生物科学
(Get Rating)
(获取评级)
Bright Minds Biosciences Inc, a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry.
Bright Minds Biosciences Inc是一家临床前生物科学公司，开发5-羟色胺(5-HT)药物，以改善严重和改变生活的疾病患者的生活。该公司的选择性5-羟色胺受体激动剂组合包括5-HT2C、5-HT2A和5-HT2C/A，用于治疗癫痫、疼痛和神经精神病学。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Bright Minds Biosciences (DRUG)
- S&P 500 Component DexCom Set For Further Price, Earnings Growth
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- 免费获取StockNews.com关于Bright Minds生物科学(药物)的研究报告
- 标准普尔500指数成分股DexCom将进一步上涨，收益增长
- MarketBeat：回顾中的一周11/7-11/11
- 油价是股市抛售尚未结束的一个令人信服的原因
- 中盘Neurocrine生物科学是井喷后的第三季度报告吗？
- 六面旗帜是一种你不想被困住的旅程
Receive News & Ratings for Bright Minds Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Bright Minds生物科学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Bright Minds Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。